ArticleBlood transfusion = Trasfusione del sangue
Evaluation of stored whole blood cellular components treated with bactericidal peptides at a higher concentration than required to assess the peptide compatibility with product quality.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advancements in screening and pathogen detection, bacterial contamination of whole blood (WB) remains a rare but critical risk, typically originating from donor blood or skin-resident bacteria. While current pathogen reduction technologies (PRT) mitigate this risk, they often compromise blood quality relative to the untreated units. As an alternative, we recently evaluated two synthetic peptides, D-CONGA and D-CONGA-Q7 in WB at a concentration of ~8 μM for bactericidal efficacy and compatibility with WB hemostasis potential. However, evaluation of hemostasis property of WB alone is insufficient to ensure that endogenous red blood cells (RBC) and platelets are maintaining other critical functional parameters that are measurable in vitro. MATERIALS AND
methodsWe investigated the effects of these peptides on the WB endogenous RBC and platelets at ~2.5 times higher concentration (i.e., 20 μM) than what is required (8 μM) for complete bactericidal activity to test their compatibility limits. We investigated the performance of WB endogenous RBC resident hemoglobin oxygen affinity and glycolytic rate as well as WB endogenous platelet aggregation potential as part of monitoring the safety and compatibility profile of the peptides.
resultsOur results support that even higher peptide concentrations do not significantly affect oxygen dissociation from red blood cells but do cause a slight deviation in P50 values and a marginal difference in glycolytic rate. Further, WB endogenous platelet aggregation is not affected by the peptide treatment with any of the aggregation agonists used. DISCUSSION: Overall, we conclude that while higher peptide concentrations (20 μM) than required for bactericidal activity (~8 μM) may slightly affect glycolysis and the ability of red blood cells to dissociate from oxygen, platelet aggregation is not affected. This report clearly supports the potential safe use of these peptides for inactivating bacteria in WB without harming the product quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.